This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / FDA Fast Track for Cocrystal Pharma's CDI-988
Regulatory regulatory approval

FDA Fast Track for Cocrystal Pharma's CDI-988

Analysis based on 7 articles · First reported Apr 02, 2026 · Last updated Apr 02, 2026

Sentiment
70
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market reacted positively to the news, with Cocrystal Pharma's shares jumping significantly. The Fast Track designation is expected to accelerate the development and review process of CDI-988, potentially bringing a new treatment for norovirus to market sooner, which could have a substantial economic impact given the global burden of the virus.

Biotechnology Pharmaceuticals
Event Summary

The United States — Food and Drug Administration has granted Fast Track designation to CDI-988, an oral antiviral candidate developed by Cocrystal Pharma for the treatment and prophylaxis of norovirus infection. This designation aims to facilitate and accelerate the development and regulatory review process for CDI-988, which is the first oral antiviral candidate for norovirus. Sam Lee, President and co-CEO of Cocrystal Pharma, emphasized the significance of this milestone for the company and patients. A Phase 1b norovirus challenge study for CDI-988 is currently underway at Emory University School of Medicine. Norovirus is a leading cause of acute gastroenteritis, responsible for an estimated 685 million global cases annually and approximately $60 billion in worldwide economic impact.

Entities Involved
stock
Cocrystal Pharma
Cocrystal Pharma received Fast Track designation from the FDA for its oral antiviral candidate, CDI-988, for norovirus infection, which is a significant milestone for the company and led to a substantial jump in its stock price.
Importance 100.0 Sentiment 75.0
per
David Lee (businessman)
Sam Lee, President and co-CEO of Cocrystal Pharma, expressed pleasure regarding the FDA's Fast Track designation for CDI-988, highlighting its importance for patients with norovirus.
Importance 60.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.